Abbott Vascular On Track For 60% Growth In 2007
This article was originally published in The Gray Sheet
Executive Summary
Abbott's vascular business is on target to achieve growth of "at least 60%" this year following a strong first quarter that saw continued success of the firm's Xience V everolimus-eluting coronary stent outside of the United States, the company says